Markets Maxim starts Armata Pharma at buy; PT $8 Maxim Group initiated coverage of Armata Pharmaceuticals (NYSE American:ARMP) with a “buy” rating and $8 price target. The stock closed at $3.71 on Feb. 5. Armata is developing phage therapies for the treatment of... February 6, 2020